The Vantive separation is expected to take place in the second half of this year, whether through a sale to a private equity firm or a spinoff into a publicly-traded company.
May 17, 2024
Medtech company Baxter International unveiled the name and logo of its proposed kidney care and acute therapies company this week.
Baxter announced the spinoff will be called Vantive, adding that the company’s tagline will be “Extending Lives, Expanding Possibilities.”
Vantive’s logo features plum coloring, incorporating Baxter’s primary brand color of blue along with the “energy and boldness” of red, per a company press release. The logo is designed with the letter “V” divided into three parts, which represent “innovative therapies, digital solutions and advanced services.”
The proposed spinoff of the kidney care company was first announced in 2023 as Baxter sought to combine its renal care and acute therapies divisions.
The separation is expected to take place in the second half of this year, whether through a sale to a private equity firm or a spinoff into a publicly-traded company.
At that point, the Vantive branding will come into effect.
Chris Toth, EVP and group president of kidney care at Baxter, will serve as CEO of Vantive upon completion of the separation.
“With the reveal of our mission and logo, we have reached another critical milestone in our journey to establish Vantive,” Toth said in a statement. “From our legacy as a pioneer in kidney care to our position as a market leader in chronic and acute therapies, we maintain a unique vantage point to help fulfill the pivotal needs of today’s clinicians and patients.”
The Vantive announcement came a couple of weeks after Baxter released its latest earnings report and raised its annual profit forecast due to strong demand for its medical devices.
Should the separation take place, Vantive will become the latest prominent, mononymous health brand spinoff from a blue-chip company.
In June 2021, GSK announced plans to divest its consumer health unit and rejected multiple bids by Unilever for the division.
Ultimately, it named the unit Haleon and spun it off in the summer of 2022.
Then, in late 2022, Johnson & Johnson announced plans to spin off consumer health unit Kenvue, which occurred in 2023.
Earlier this spring, 3M completed the planned spinoff of its healthcare business into Solventum.
